118 related articles for article (PubMed ID: 20839950)
1. Triple-negative breast cancer: unique biology and its management.
Maegawa RO; Tang SC
Cancer Invest; 2010 Oct; 28(8):878-83. PubMed ID: 20839950
[TBL] [Abstract][Full Text] [Related]
2. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
Santarosa M; Maestro R
Cancer Metastasis Rev; 2012 Jun; 31(1-2):131-42. PubMed ID: 22101651
[TBL] [Abstract][Full Text] [Related]
3. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
Greenberg S; Rugo HS
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity of triple-negative breast cancer and its clinical implications.
Irshad S; Ellis P; Tutt A
Curr Opin Oncol; 2011 Nov; 23(6):566-77. PubMed ID: 21986848
[TBL] [Abstract][Full Text] [Related]
5. Triple negative breast cancer: from molecular portrait to therapeutic intervention.
Carotenuto P; Roma C; Rachiglio AM; Botti G; D'Alessio A; Normanno N
Crit Rev Eukaryot Gene Expr; 2010; 20(1):17-34. PubMed ID: 20528735
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK; Cryns VL; Symmans WF; Sneige N
Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
[TBL] [Abstract][Full Text] [Related]
7. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
9. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
10. Beyond triple-negative breast cancer: the need to define new subtypes.
Constantinidou A; Jones RL; Reis-Filho JS
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1197-213. PubMed ID: 20735307
[TBL] [Abstract][Full Text] [Related]
11. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
Venkitaraman R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancer: a brief review of its characteristics and treatment options.
Griffiths CL; Olin JL
J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
16. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Silva E; Gatalica Z; Snyder C; Vranic S; Lynch JF; Lynch HT
Breast J; 2008; 14(1):14-24. PubMed ID: 18086271
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer: risk factors to potential targets.
Schneider BP; Winer EP; Foulkes WD; Garber J; Perou CM; Richardson A; Sledge GW; Carey LA
Clin Cancer Res; 2008 Dec; 14(24):8010-8. PubMed ID: 19088017
[TBL] [Abstract][Full Text] [Related]
18. Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.
Johansson I; Aaltonen KE; Ebbesson A; Grabau D; Wigerup C; Hedenfalk I; Rydén L
Genes Chromosomes Cancer; 2012 Apr; 51(4):375-83. PubMed ID: 22170730
[TBL] [Abstract][Full Text] [Related]
19. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
[TBL] [Abstract][Full Text] [Related]
20. Management of triple negative breast cancer.
Oakman C; Viale G; Di Leo A
Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]